Antibody Information
General Information of This Antibody
| Antibody ID | ANI0WCBXH |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Anti-EDB-FN L19 |
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG1-kappa |
|||||
| Antigen Name | Fibronectin (FN1) |
Antigen Info | ||||
The Activity Data of This Antibody
| Antibody Activity Information 1 | [1] | |||||
|
Dissociation Constant (Kd)
|
43.10±6.08
|
pM
|
||||
|---|---|---|---|---|---|---|
| Antibody Function | Confirm the effect of the drug conjugation with the anti EDB-FN mAb and ADC on binding activity to cell line. | |||||
| Antibody Antigen Binding Assay | Using a different SPR approach, where EDB was directly coupled to the biosensor chip and L19 used as the analyte,. | |||||
| Antibody Activity Information 2 | [1] | |||||
|
Dissociation Constant (Kd)
|
231.00±1.40
|
nM
|
||||
| Antibody Function | Confirm the effect of the drug conjugation with the anti EDB-FN mAb and ADC on binding activity to cell line. | |||||
| Antibody Antigen Binding Assay | The binding affinity (KD) of anti-EDB+FN L19 antibody for human 7-EDB-89 (EDB) was determined. | |||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
EDB-ADC [Investigative]
Discovered Using Patient-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 0.00% (Day 14) | High FN1 expression (FN1+++) | ||
| Method Description |
EDB+FN expression was evaluated in NSCLC and pancreatic cancer xenografts in immunocompromised mice using IHC. Mice were treated intravenously every 4 days with phosphate-buffered saline (PBS),Neg-vc0101 (Neg-ADC),EDC-vc0101 (EDB-ADC). This tumor model was injected intravenously with EDB-ADC 0.75 mg/kg q4dx4.
|
||||
| In Vivo Model | Pancreatic cancer PDX model (PDX: PDX-PAX-13565) | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 26.20% (Day 14) | High FN1 expression (FN1+++) | ||
| Method Description |
EDB+FN expression was evaluated in NSCLC and pancreatic cancer xenografts in immunocompromised mice using IHC. Mice were treated intravenously every 4 days with phosphate-buffered saline (PBS),Neg-vc0101 (Neg-ADC),EDC-vc0101 (EDB-ADC). This tumor model was injected intravenously with EDB-ADC 1.5 mg/kg q4dx4.
|
||||
| In Vivo Model | Pancreatic cancer PDX model (PDX: PDX-PAX-13565) | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 43.20% (Day 28) | High FN1 expression (FN1+++) | ||
| Method Description |
EDB+FN expression was evaluated in NSCLC and pancreatic cancer xenografts in immunocompromised mice using IHC. Mice were treated intravenously every 4 days with phosphate-buffered saline (PBS),Neg-vc0101 (Neg-ADC),EDC-vc0101 (EDB-ADC). This tumor model was injected intravenously with EDB-ADC 0.3 mg/kg q4dx4.
|
||||
| In Vivo Model | Nonsmall cell lung cancer PDX model (PDX: PDX-NSX-11122) | ||||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 79.30% (Day 28) | High FN1 expression (FN1+++) | ||
| Method Description |
EDB+FN expression was evaluated in NSCLC and pancreatic cancer xenografts in immunocompromised mice using IHC. Mice were treated intravenously every 4 days with phosphate-buffered saline (PBS),Neg-vc0101 (Neg-ADC),EDC-vc0101 (EDB-ADC). This tumor model was injected intravenously with EDB-ADC 1 mg/kg q4dx4.
|
||||
| In Vivo Model | Nonsmall cell lung cancer PDX model (PDX: PDX-NSX-11122) | ||||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 87.80% (Day 14) | High FN1 expression (FN1+++) | ||
| Method Description |
EDB+FN expression was evaluated in NSCLC and pancreatic cancer xenografts in immunocompromised mice using IHC. Mice were treated intravenously every 4 days with phosphate-buffered saline (PBS),Neg-vc0101 (Neg-ADC),EDC-vc0101 (EDB-ADC). This tumor model was injected intravenously with EDB-ADC 3 mg/kg q4dx4.
|
||||
| In Vivo Model | Pancreatic cancer PDX model (PDX: PDX-PAX-13565) | ||||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 97.20% (Day 28) | High FN1 expression (FN1+++) | ||
| Method Description |
EDB+FN expression was evaluated in NSCLC and pancreatic cancer xenografts in immunocompromised mice using IHC. Mice were treated intravenously every 4 days with phosphate-buffered saline (PBS),Neg-vc0101 (Neg-ADC),EDC-vc0101 (EDB-ADC). This tumor model was injected intravenously with EDB-ADC 3 mg/kg q4dx4.
|
||||
| In Vivo Model | Nonsmall cell lung cancer PDX model (PDX: PDX-NSX-11122) | ||||
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 67.00% (Day 15) | High FN1 expression (FN1+++) | ||
| Method Description |
EDB+FN expression was evaluated in NSCLC and pancreatic cancer xenografts in immunocompromised mice using IHC. Athymic nu/nu nude mice were injected subcutaneously in the right flank with 8 10 6 cells suspended in 100% Matrigel. This tumor model was injected intravenously with EDB-ADC 1 mg/kg q4dx4.
|
||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1975 cells | CVCL_1511 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 80.10% (Day 15) | High FN1 expression (FN1+++) | ||
| Method Description |
EDB+FN expression was evaluated in NSCLC and pancreatic cancer xenografts in immunocompromised mice using IHC. Athymic nu/nu nude mice were injected subcutaneously in the right flank with 8 10 6 cells suspended in 100% Matrigel. This tumor model was injected intravenously with EDB-ADC 3 mg/kg q4dx4.
|
||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1975 cells | CVCL_1511 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 30) | High FN1 expression (FN1+++) | ||
| Method Description |
EDB+FN expression was evaluated in NSCLC and pancreatic cancer xenografts in immunocompromised mice using IHC. Athymic nu/nu nude mice were injected subcutaneously in the right flank with 8 10 6 cells suspended in 100% Matrigel. This tumor model was injected intravenously with EDB-ADC 3 mg/kg q4dx4.
|
||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1975 cells | CVCL_1511 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.